John is Vice President of API (Active Pharmaceutical Ingredients) Technology Operations, Pfizer Global Supply. He began his career at Bristol-Myers Squibb as a Research Scientist in 1983 and progressed through positions of increasing responsibility culminating in his appointment as Director of Chemical Development Labs.
He joined Honeywell in 2000 as Global Head of Technology for the Pharmaceutical Fine Chemical Business. In 2001 he joined Schering-Plough where he was responsible for Technology Transfer of API (Small-molecule and Biotech) from Research to Manufacturing as well as for Validation of API processes under the consent decree.
In 2008, he joined Wyeth as Vice President of New Products, Process Development with responsibility for late development and commercialization of API's. After the acquisition of Wyeth by Pfizer, he was appointed to his current position with responsibility for development of new processes for commercial API's to reduce cost.
John received his B.S. in Chemistry magna cum laude from Syracuse University and a PhD in Organic Chemistry from the State University of New York at Binghamton.